Darzalex 400MG Injection (20ml), containing the active ingredient Daratumumab, is a monoclonal antibody specifically designed for the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. This innovative medication works by targeting CD38, a protein that is highly expressed on the surface of myeloma cells, leading to their destruction. Darzalex is typically administered intravenously and is often used in combination with other therapies to enhance its effectiveness. The formulation comes in a 20ml vial, providing a concentrated dose of 400mg of Daratumumab, which is crucial for patients undergoing treatment for this challenging condition. As a targeted therapy, Darzalex represents a significant advancement in the management of multiple myeloma, offering hope for improved outcomes and quality of life for patients.